Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (CDTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cdtx · stock forecast · 11 analysts (3M) · FMP · updated Feb 6, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$222
Consensus
$178
-19.6% upside
Low
$150
Median: $170 · Last Close: $221.38
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$177.88
-19.6% upside
High Target
$221.5
0.1%
Low Target
$150
-32.2%
Current Price
$221.38
as of today
Based on analyst price targets, the CDTX stock price prediction for the next 12 months ranges from $150 to $221.5. The consensus CDTX price forecast of $177.88 implies -19.6% upside from the current price of $221.38.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $221.08 | ↓ 0.14% |
1-day model range: $221.01–$221.14. Peak: $221.14 (-0.14%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CDTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-18 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2025-11-14 | Needham | Downgrade ↓ | Buy→Hold |
| 2025-11-14 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-11-07 | Needham | Maintains | Buy→Buy |
| 2025-11-07 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-10-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-09 | WBB Securities | Maintains | Strong Buy→Strong Buy |
| 2025-10-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-03 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-09-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cidara Therapeutics, Inc. (CDTX) stock. Of the recent 73 rating actions, 6 were upgrades and 6 were downgrades. 11 analysts currently cover CDTX.
Analyst Recommendation Trends
CDTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$54M
↑ 357.9% YoY
Revenue Next Year
$8M
↓ 84.3% YoY
EPS This Year
$-7.63
EPS Next Year
$-6.24
↓ 18.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CDTX EPS of $-7.63 for the current fiscal year, based on estimates from 4 analysts. The CDTX revenue forecast is $54M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CDTX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CDTX price target is $177.88 (-19.6% upside), with an analyst consensus of Buy.
The CDTX short-term stock prediction for tomorrow is $221.08 (-0.14%).
Cidara Therapeutics, Inc. trades on NASDAQ under the ticker CDTX. The CDTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 73% of covering analysts.
Frequently asked questions
CDTX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month CDTX price target is $177.88, with a high forecast of $221.50 and a low of $150.00. The median price target is shown in the chart above when available. This implies -19.6% potential upside from the current price of $221.38.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.